Last reviewed · How we verify
Gemcitabine cisplatin followed by docetaxel
Gemcitabine is a nucleoside analog that inhibits DNA synthesis, while cisplatin is a platinum-based alkylating agent that cross-links DNA, and docetaxel is a taxane that stabilizes microtubules.
Gemcitabine is a nucleoside analog that inhibits DNA synthesis, while cisplatin is a platinum-based alkylating agent that cross-links DNA, and docetaxel is a taxane that stabilizes microtubules. Used for Non-small cell lung cancer, Ovarian cancer, Pancreatic cancer.
At a glance
| Generic name | Gemcitabine cisplatin followed by docetaxel |
|---|---|
| Sponsor | Sanofi |
| Drug class | Cytotoxic chemotherapy |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Gemcitabine, cisplatin, and docetaxel work synergistically to induce apoptosis in cancer cells. Gemcitabine inhibits DNA synthesis, while cisplatin cross-links DNA, and docetaxel stabilizes microtubules, ultimately leading to cell death.
Approved indications
- Non-small cell lung cancer
- Ovarian cancer
- Pancreatic cancer
Common side effects
- Neutropenia
- Nausea and vomiting
- Fatigue
- Diarrhea
- Anemia
Key clinical trials
- Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) (PHASE3)
- A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) (PHASE2, PHASE3)
- Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC) (PHASE2)
- Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010] (PHASE3)
- Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC (PHASE2)
- Secondary Cytoreductive Surgery After Chemotherapy for Recurrent Epithelial Ovarian Cancer (PHASE2)
- Watch-and-Wait After Immunochemotherapy in Locally Recurrent Nasopharyngeal Carcinoma
- ctDNA to Predict Response to Chemo-Immunotherapy and Detect Minimal Residual Disease in Non-Small Cell Lung Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gemcitabine cisplatin followed by docetaxel CI brief — competitive landscape report
- Gemcitabine cisplatin followed by docetaxel updates RSS · CI watch RSS
- Sanofi portfolio CI